Arrowhead Pharmaceuticals

This Phase 3 study tested a drug called plozasiran (ARO-APOC3) in 75 adults with familial chylomicronemia syndrome, a rare genetic disorder causing extremely high blood fat levels and risk of pancreatitis. Participants received four injections of the drug or a placebo over severa…

This completed early-stage trial tested an experimental drug called ARO-C3 in 62 healthy volunteers and patients with two types of kidney disease (C3 glomerulopathy and IgA nephropathy). The drug is designed to calm an overactive part of the immune system that can damage the kidn…

This early-stage trial tested a drug called ARO-CFB in 49 healthy volunteers and people with IgA nephropathy, a kidney disease where the immune system damages the kidneys. The main goal was to check safety and how the drug moves through the body. Participants received either one …

This study looked at the long-term safety of a drug called ARO-APOC3 in adults with dyslipidemia (abnormal fat levels in the blood). Participants who completed a previous 12-month study could continue receiving the drug every 3 or 6 months. The goal was to see if the drug remains…

This phase 2b trial tested plozasiran, an experimental drug, in 353 adults with mixed dyslipidemia (high triglycerides and cholesterol). Participants received either plozasiran or a placebo, and researchers measured changes in blood fat levels over 48 weeks. The goal is to see if…

This study tested an experimental drug called ARO-APOC3 in 229 adults with severely high triglycerides (a type of blood fat). Participants received two injections of the drug or a placebo. The goal was to see if the drug could safely lower triglyceride levels. Results showed sign…

This early-stage study tested a new medicine called ARO-ANG3 in 93 people, including healthy volunteers and patients with high cholesterol or high triglycerides. The main goal was to check if the drug is safe and how the body processes it. This research helps determine if the dru…

This early-stage study tested a new medicine called ARO-APOC3 in healthy volunteers and people with severely high triglycerides or a rare genetic condition called familial chylomicronemia syndrome. The main goal was to check safety and how the drug moves through the body. The stu…

This phase 2b trial tested an experimental drug called ARO-ANG3 in 204 adults with mixed dyslipidemia, a condition with high triglycerides and cholesterol. Participants received injections of the drug or a placebo over several months. The goal was to see if the drug safely lowers…

This Phase 2 study tested a drug called fazirsiran in 40 adults with Alpha-1 antitrypsin deficiency, a genetic condition that can cause liver disease. The drug is designed to lower levels of a harmful protein (Z-AAT) in the blood. Researchers measured safety and how much the prot…

This study tested an experimental drug called ARO-HBV in healthy volunteers and people with chronic hepatitis B. The drug uses RNA interference to try to stop the virus from multiplying. The main goal was to check safety and how the body processes the drug, not yet to prove it wo…

This study tested an inhaled drug called ARO-MMP7 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal was to check safety and how the body handles the drug. About 105 participants took p…

This study tested a drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The drug aims to reduce harmful protein buildup in the liver. Researchers measured changes in liver protein levels and safety over 24 to 4…

This study tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had gotten worse after other treatments. The main goal was to find a safe dose and check for side effects. This is an early-phase trial, so it focuses on safety and dosing, not y…

This study tested an experimental drug called ARO-HSD in 50 healthy volunteers and people with NASH, a serious fatty liver disease. The main goal was to check safety and how the drug moves through the body. It's an early step to see if ARO-HSD might be a future treatment for NASH…

This early-stage study tested an inhaled medication called ARO-RAGE in 127 healthy volunteers and people with asthma. The goal was to check safety and how the drug affects lung function. Participants received one or two doses of the drug or a placebo. Results will help decide if …

This early-stage study tested the safety and how the body processes ARC-520, an experimental drug for hepatitis B, in 40 healthy adults. Participants received a single dose at different infusion speeds. The goal was to check for side effects and measure drug levels in the blood, …

This early-stage study tested the safety and how the body processes a new drug called ARO-AAT in 45 healthy adults. The goal was to see if the drug is safe and to measure its levels in the blood. This research is a first step toward a possible treatment for Alpha-1 Antitrypsin De…

This early-stage study tested the safety and how the body processes ARC-520 in 54 healthy adults aged 18-55. Participants received either the drug or a placebo to check for side effects. The goal was not to treat any disease but to gather safety information for future research.